CompletedPhase 4

Comparison of Exenatide and Metformin Monotherapy in Overweight/Obese Patients With Newly Diagnosed Type 2 Diabetes

Beijing Chao-Yang Hospital, Capital Medical University

Lead sponsor

Beijing Chao Yang Hospital

Asset

Exenatide

GLP-1 agonist

Listed sites

Recruiting sites

Actual enrollment

230

Study population

Obesity / overweight, Type 2 diabetes

Eligibility highlights

•BMI ≥24•HbA1c ≥7%

Primary endpoint

•HbA1c, change

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT03297879

Org study ID2015-科 144

Timeline

Milestones

Study start2013-01-01actual

Primary completion2016-02-28actual

Study completion2016-02-28actual

Study first posted2017-09-29actual

Last update posted2017-10-02actual

Assets

Investigational agents

Exenatide

Who this study enrolls

Obesity / overweightType 2 diabetes

Who can enroll

Minimum age20 Years

Maximum age65 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•age 20 - <65 years,

•body mass index (BMI) ≥ 24 kg/m2,

•HbA1c ≥ 7% (53mmol/mol).

•diabetes antibodies (-)

•diagnosed with T2D within the previous 3 months

Exclusion criteria

•anti-diabetic drugs or diet therapy before participation

•pancreatitis

•coronary artery disease

•liver function impairment

•renal function impairment

•intestinal surgery

•chronic hypoxic diseases (emphysema and cor pulmonale)

•infectious disease

•hematological disease

•systemic inflammatory disease

•cancer

•pregnant, possibly pregnant

•ingesting agents known to influence glucose or lipid metabolism

Endpoints (1)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Glycemic / diabetes

1 endpoint

Primary/protocol endpoint

The change of HbA1c

Time frame:baseline and 12 weeks

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Publications (2)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

The Changes of Lipidomic Profiles Reveal Therapeutic Effects of Exenatide in Patients With Type 2 Diabetes.
Frontiers in endocrinology2022 (year)PMID35432194doi:10.3389/fendo.2022.677202via clinicaltrials gov reference derived + pubmed nct search
Comparison of Exenatide and Metformin Monotherapy in Overweight/Obese Patients with Newly Diagnosed Type 2 Diabetes.
International journal of endocrinology2017 (year)PMID29358950doi:10.1155/2017/9401606via clinicaltrials gov reference derived + pubmed nct search

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 6, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.